Equetro Related Published Studies
Well-designed clinical trials related to Equetro (Carbamazepine)
The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study. [2008.07]
Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations? [2008.02]
Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. [2008.01]
The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. [2007.12]
Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. [2007.11.27]
Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. [2007.11]
The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. [2007.09]
Lack of Pharmacokinetic Interaction of Levetiracetam on Carbamazepine, Valproic Acid, Topiramate, and Lamotrigine in Children with Epilepsy. [2007.07.25]
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. [2007.07]
Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. [2007.06.09]
Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. [2007.04]
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. [2007.03.24]
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. [2007.02.06]
Biopharmaceutical characterization of carbamazepine immediate release tablets. In vitro-in vivo comparison. [2007]
Efficacy of carbamazepine and valproate as monotherapy for early epilepsy and single seizures. [2006.11.28]
Bronchial asthma as neurogenic paroxysmal inflammatory disease: A randomized trial with carbamazepine. [2006.11]
Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. [2006.07]
Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. [2006.07]
Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. [2006.02]
Lamotrigine versus carbamazepine monotherapy for epilepsy. [2006.01.25]
Modulation of serum concentrations of melatonin by carbamazepine and valproate. [2006.01]
Chronotherapeutic dose schedule of phenytoin and carbamazepine in epileptic patients. [2006]
The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. [2005.12]
A comparative study of vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial seizures in children. [2005.09]
Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. [2005.09]
[Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study] [2005.07]
The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit. [2005.07]
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. [2005.06.14]
Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. [2005.06]
Induction of the metabolism of etizolam by carbamazepine in humans. [2005.05]
Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. [2005.03]
Well-designed clinical trials possibly related to Equetro (Carbamazepine)
A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. [2008.06]
Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). [2008.03]
Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. [2008.02.12]
The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: a systematic review. [2008.02]
Gabapentin supplemented with ropivacain block of trigger points improves pain control and quality of life in trigeminal neuralgia patients when compared with gabapentin alone. [2008.01]
Bioequivalence study of two formulations containing 400 mg dexibuprofen in healthy Indian subjects. [2008]
The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies. [2007.11]
Lamotrigine extended-release as adjunctive therapy for partial seizures. [2007.10.16]
Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy--a prospective randomized double-blind withdrawal study. [2007.10]
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. [2007.09]
Management of neuropathic pain. [2007.08]
Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. [2007.07]
Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. [2007.07]
Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers? [2007.07]
The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. [2007.06]
How reliable is early treatment response in predicting long-term seizure outcome? [2007.06]
Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): An open-label, parallel group trial. [2007.06]
Are serum lithium levels related to the polarity of recurrence in bipolar disorders? Evidence from a multicenter trial. [2007.05]
Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder. [2007.05]
Choosing a First Drug Treatment for Epilepsy after SANAD: Randomized Controlled Trials, Systematic Reviews, Guidelines and Treating Patients. [2007.04.18]
High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. [2007.04]
Long-term safety and tolerability of oxcarbazepine in painful diabetic neuropathy. [2007.04]
Diagnostics for confounding in PK/PD models for oxcarbazepine. [2007.01.30]
Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. [2007]
Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. [2006.12]
A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. [2006.09]
A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder. [2006.08.30]
Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. [2006.08.22]
Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. [2006.08.08]
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. [2006.07.19]
Non-antiepileptic drugs for trigeminal neuralgia. [2006.07.19]
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. [2006.07]
A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. [2006.07]
Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. [2006.06]
Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. [2006.06]
Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. [2006.05]
Randomized trial to improve laboratory safety monitoring of ongoing drug therapy in ambulatory patients. [2006.05]
Oxcarbazepine versus phenytoin monotherapy for epilepsy. [2006.04.19]
A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. [2006.04]
Risperidone treatment of bipolar mania. [2006.04]
A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. [2006.03]
[Use of antiepileptic drugs in bipolar disorder] [2006.01]
Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. [2005.12]
Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. [2005.12]
Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. [2005.11.08]
Oxcarbazepine as add-on therapy in Thai epileptic patients with refractory partial seizures. [2005.11]
Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. [2005.10]
Anticonvulsants for alcohol withdrawal. [2005.07.20]
Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital. [2005.07]
Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. [2005.06]
Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. [2005.06]
[Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid] [2005.04.16]
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. [2005.03]
Differential effects of neuropathic analgesics on wind-up-like pain and somatosensory function in healthy volunteers. [2005.03]
Topiramate monotherapy in epilepsy and migraine prevention. [2005.02]
A comparison of anticonvulsants in the treatment of impulsive aggression. [2005.02]
[The risk of second seizure in children with benign childhood epilepsy with centrotemporal spikes without treatment--a prospective study] [2005]
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. [2005]
Other research related to Equetro (Carbamazepine)
Effects of carbamazepine on spinal cord ischemia. [2008.10]
Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. [2008.08]
Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy. [2008.07.29]
Tendon sheath abscess and severe carbamazepine hypersensitivity. [2008.07]
Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple-Dose Administration in Healthy Subjects. [2008.06.02]
Treatment of alcohol withdrawal syndrome with carbamazepine, gabapentin, and nitrous oxide. [2008.06.01]
Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine. [2008.06]
Psychosis with frontal lobe epilepsy responds to carbamazepine. [2008.04]
Carbamazepine as the only effective treatment in a 52-year-old man with trigeminal trophic syndrome. [2008.04]
Evaluation of the factors affecting the quality of life and total costs in epilepsy patients on monotherapy with carbamazepine and valproate. [2008.04]
Changes in gene expression induced by carbamazepine and phenytoin: testing the danger hypothesis. [2008.04]
Seromucosal transport of intravenously administered carbamazepine is not enhanced by oral doses of activated charcoal in rats. [2008.03]
|
